201920182017201620152014 May 09, 2019 Summary ToggleSpero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review May 01, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 08, 2019 Summary ToggleSpero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases March 29, 2019 Summary ToggleSpero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis March 19, 2019 Summary ToggleSpero Announces Appointment of Cynthia Smith to its Board of Directors March 14, 2019 Summary ToggleSpero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review March 01, 2019 Summary ToggleSpero Therapeutics to Present at March Investor Conferences February 26, 2019 Summary ToggleSpero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720 February 04, 2019 Summary ToggleSpero Therapeutics Announces FDA Acceptance of IND Application for SPR994 January 29, 2019 Summary ToggleSpero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
